-
×
Mildronate capsules 500mg, 90pcs
$110.0 -
×
OKI, sachets 80mg 2g, 12pcs
$44.0 -
×
Cavinton Comfort, dispersible pills 10mg 90pcs
$49.0 -
×
Cortexin, 10mg, 5ml, 10pcs
$278.0 -
×
Phenibut-Vertex pills 250mg, 20pcs
$84.0 -
×
Picamilon pills 50mg, 60pcs
$22.5 -
×
Belosalic, ointment, 30g
$106.0
Iodopyron (Solution) Instructions for Use
ATC Code
D08AG (Iodine preparations)
Active Substance
Povidone-iodine (BAN)
Clinical-Pharmacological Group
Antiseptic for external use
Pharmacotherapeutic Group
Antiseptics and disinfectants; iodine preparations
Pharmacological Action
Antiseptic and disinfectant agent. When released from the complex with polyvinylpyrrolidone upon contact with the skin and mucous membranes, iodine forms iodamines with bacterial cell proteins, coagulates them, and causes the death of microorganisms.
It has a rapid bactericidal effect on gram-positive and gram-negative bacteria (except for Mycobacterium tuberculosis). It is effective against fungi, viruses, and protozoa.
Pharmacokinetics
With topical application, almost no absorption of iodine occurs.
Indications
Treatment and prevention of wound infections in surgery, traumatology, combustiology, and dentistry; treatment of bacterial, fungal, and viral skin infections, prevention of superinfection in dermatological practice; treatment of bedsores, trophic ulcers, diabetic foot; disinfection of the skin and mucous membranes of patients in preparation for surgical interventions, invasive studies (including punctures, biopsies, injections); disinfection of the skin around drains, catheters, probes; disinfection of the oral cavity during dental operations; disinfection of the birth canal, during “minor” gynecological operations (including artificial termination of pregnancy, insertion of an IUD, coagulation of erosion and polyp). For hygienic treatment of the hands of surgeons and medical personnel.
ICD codes
Open the list of ICD codes
| ICD-10 code | Indication |
| A60 | Anogenital herpesviral infection [herpes simplex] |
| B00 | Herpesviral [herpes simplex] infections |
| B01 | Varicella [chickenpox] |
| B35.2 | Mycosis of hands |
| B35.3 | Tinea pedis |
| B35.4 | Tinea corporis |
| B35.6 | Tinea cruris |
| B37.2 | Candidiasis of skin and nails |
| E10.5 | Insulin-dependent diabetes mellitus with peripheral circulatory complications (including ulcer, gangrene) |
| E11.5 | Non-insulin-dependent diabetes mellitus with peripheral circulatory complications (including ulcer, gangrene) |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| L30.3 | Infectious dermatitis (infectious eczema) |
| L89 | Decubitus ulcer and pressure area |
| L98.4 | Chronic skin ulcer, not elsewhere classified |
| T14.0 | Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect) |
| T14.1 | Open wound of unspecified body region |
| T30 | Burns and corrosions of unspecified body region |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| Z93 | Artificial opening status |
| ICD-11 code | Indication |
| 1A94.Z | Anogenital herpes simplex virus infection without further specification |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1E90.Z | Varicella, unspecified |
| 1F00.Z | Infections due to herpes simplex virus, unspecified |
| 1F23.1Z | Candidiasis of skin or mucous membranes, unspecified |
| 1F28.2 | Dermatophytosis of foot |
| 1F28.3 | Genitofemoral dermatophytosis |
| 1F28.Y | Other specified dermatophytosis |
| 5A10 | Type 1 diabetes mellitus |
| 5A11 | Type 2 diabetes mellitus |
| EA40 | Tropical phagedenic ulcer |
| EA50.3 | Staphylococcal scarlet fever |
| EA88.0Z | Infectious dermatitis, unspecified |
| EB21 | Pyoderma gangrenosum |
| EF60 | Ischemic ulceration of the skin |
| EH90.Z | Pressure ulcer of unspecified degree |
| EH92 | Dermatoses provoked by friction or mechanical impact |
| EH92.1 | Blister due to friction |
| EM0Z | Unspecified skin disorder |
| ME60.2 | Ulcerative skin lesion of unspecified nature |
| ND56.0 | Superficial injury of unspecified body region |
| ND56.1 | Open wound of unspecified body region |
| NE11 | Burn of unspecified body region |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| QB61.Z | Presence of artificial opening, unspecified |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Solution
It is used externally and topically.
For external use, the damaged areas of the skin are treated with iodine.
Topically, it is used for washing lacunae and supratonsillar spaces, for irrigating the nasopharynx, for instillation into the ear and washing; in surgical practice and for burns, gauze napkins applied to the affected surface are moistened as needed. The doses, method of application, and duration of treatment are determined depending on the indications.
Adverse Reactions
Possibly with frequent application over a large area of the wound surface and mucous membranes, systemic resorption of iodine may occur, which may affect thyroid function tests. Hypersensitivity reactions, manifestations of an allergic reaction (hyperemia, burning, itching, swelling, pain) are possible, which requires discontinuation of povidone-iodine.
Contraindications
Hypersensitivity to iodine; thyroid dysfunction (hyperthyroidism); thyroid adenoma; Duhring’s herpetiformis dermatitis; simultaneous use of radioactive iodine; premature and newborn infants.
With caution
Chronic renal failure, pregnancy, breastfeeding period.
Use in Pregnancy and Lactation
The use of povidone-iodine is not recommended from the 3rd month of pregnancy and during the lactation (breastfeeding) period. If necessary in these cases, treatment is possible under individual medical supervision.
Use in Renal Impairment
Caution should be exercised with regular use on damaged skin in patients with chronic renal failure.
Pediatric Use
Contraindication: premature and newborn infants.
Geriatric Use
Use with caution in elderly patients to avoid the risk of exacerbation of chronic diseases.
Special Precautions
In case of thyroid dysfunction, the use of the drug is possible only under strict medical supervision.
Caution should be exercised with regular use on damaged skin in patients with chronic renal failure.
A colored film forms at the application site, which persists until the entire amount of active iodine is released, which means the cessation of the active substance’s action.
The color on the skin and tissues is easily washed off with water.
Do not use for insect bites, domestic and wild animal bites.
Drug Interactions
Incompatible with other antiseptic agents, especially those containing alkalis, enzymes, and mercury.
In the presence of blood, the bactericidal effect may decrease, but by increasing the concentration of the active substance, bactericidal activity can be increased.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Iodopyron [West, LLC (Russia)]
Solution for external use 1%: fl. 10 ml, 15 ml, 25 ml, 50 ml, or 100 ml
Solution for external use 1%: fl. 10 ml, 15 ml, 25 ml, 50 ml, or 100 ml
Marketing Authorization Holder
West, LLC (Russia)
Manufactured By
Technopark-Center LLC (Russia)
Or
Samaramedprom, OJSC (Russia)
Dosage Form
 |
Iodopyron | Solution for external use 1%: fl. 10 ml, 15 ml, 25 ml, 50 ml, or 100 ml |
Dosage Form, Packaging, and Composition
Solution for external use 1% in the form of a film-forming dark brown liquid without odor or with a weak specific odor.
| 1000 ml | |
| Povidone-iodine | 136.2 g |
Excipients: potassium iodide – 13.8 g, purified water – up to 1000 ml.
10 ml – bottles (1) – cardboard packs.
15 ml – bottles (1) – cardboard packs.
25 ml – bottles (1) – cardboard packs.
50 ml – bottles (1) – cardboard packs.
100 ml – bottles (1) – cardboard packs.
250 ml – bottles (20) – cardboard boxes (for hospitals).
330 ml – bottles (16) – cardboard boxes (for hospitals).
500 ml – bottles (12) – cardboard boxes (for hospitals).
1 L – bottles (8) – cardboard boxes (for hospitals).
4.5 L – bottles (4) – cardboard boxes (for hospitals).
Iodopyron [Genel RD, LLC (Russia)]
Solution for external use 1%: fl. 10 ml, 15 ml, 25 ml, 50 ml, or 100 ml
Solution for external use 1%: fl. 10 ml, 15 ml, 25 ml, 50 ml, or 100 ml
Marketing Authorization Holder
Genel RD, LLC (Russia)
Manufactured By
Technopark-Center LLC (Russia)
Or
Samaramedprom, OJSC (Russia)
Dosage Form
|
Iodopyron | Solution for external use 1%: fl. 10 ml, 15 ml, 25 ml, 50 ml, or 100 ml |
Dosage Form, Packaging, and Composition
Solution for external use in the form of a film-forming dark brown liquid without odor or with a weak specific odor.
| 1 L | |
| Povidone-iodine* | 136.2 g |
* in the form of a polyvinylpyrrolidone iodine complex.
Excipients: potassium iodide – 13.8 g, purified water – up to 1000 ml.
10 ml – glass bottles (1) – cardboard packs.
15 ml – glass bottles (1) – cardboard packs.
25 ml – glass bottles (1) – cardboard packs.
50 ml – glass bottles (1) – cardboard packs.
100 ml – glass bottles (1) – cardboard packs.
Iodopyron [Tula Pharmaceutical Factory, LLC (Russia)]
Solution for external use 1%: fl. or dropper fl. or jars 10 ml, 15 ml, 20 ml, 25 ml, 30 ml, 40 ml, 50 ml, 90 ml, or 100 ml
Solution for external use 1%: fl. or dropper fl. or jars 10 ml, 15 ml, 20 ml, 25 ml, 30 ml, 40 ml, 50 ml, 90 ml, or 100 ml
Marketing Authorization Holder
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
|
Iodopyron | Solution for external use 1%: fl. or dropper fl. or jars 10 ml, 15 ml, 20 ml, 25 ml, 30 ml, 40 ml, 50 ml, 90 ml, or 100 ml |
Dosage Form, Packaging, and Composition
Solution for external use in the form of a film-forming dark brown liquid, without odor or with a weak characteristic odor.
| 1 L | |
| Iodine | 14.1 g |
Excipients: potassium iodide – 13.8 g, povidone K17 – 122.1 g, purified water – up to 1 L.
10 ml – dropper bottles (1) – cardboard packs.
15 ml – dropper bottles (1) – cardboard packs.
20 ml – dropper bottles (1) – cardboard packs.
25 ml – dropper bottles (1) – cardboard packs.
30 ml – dropper bottles (1) – cardboard packs.
40 ml – dropper bottles (1) – cardboard packs.
50 ml – dropper bottles (1) – cardboard packs.
90 ml – dropper bottles (1) – cardboard packs.
100 ml – dropper bottles (1) – cardboard packs.
10 ml – bottles* (1) – cardboard packs.
15 ml – bottles* (1) – cardboard packs.
20 ml – bottles* (1) – cardboard packs.
25 ml – bottles* (1) – cardboard packs.
30 ml – bottles* (1) – cardboard packs.
40 ml – bottles* (1) – cardboard packs.
50 ml – bottles* (1) – cardboard packs.
90 ml – bottles* (1) – cardboard packs.
100 ml – bottles* (1) – cardboard packs.
10 ml – jars* (1) – cardboard packs.
15 ml – jars* (1) – cardboard packs.
20 ml – jars* (1) – cardboard packs.
25 ml – jars* (1) – cardboard packs.
30 ml – jars* (1) – cardboard packs.
40 ml – jars* (1) – cardboard packs.
50 ml – jars* (1) – cardboard packs.
90 ml – jars* (1) – cardboard packs.
100 ml – jars* (1) – cardboard packs.
* with a stopper or dropper cap
Iodopyron [Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)]
Solution for external use 1%: fl. 10 ml, 15 ml, 20 ml, 25 ml, 30 ml, 40 ml, 50 ml, or 100 ml
Solution for external use 1%: fl. 10 ml, 15 ml, 20 ml, 25 ml, 30 ml, 40 ml, 50 ml, or 100 ml
Marketing Authorization Holder
Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)
Dosage Form
|
Iodopyron | Solution for external use 1%: fl. 10 ml, 15 ml, 20 ml, 25 ml, 30 ml, 40 ml, 50 ml, or 100 ml |
Dosage Form, Packaging, and Composition
Solution for external use in the form of a film-forming dark brown liquid, without odor or with a weak characteristic odor.
| 1000 ml | |
| Iodine | 14.1 g |
Excipients: potassium iodide – 13.8 g, povidone K17 – 122.1 g, purified water – up to 1000 ml.
10 ml – bottles (1) – cardboard packs.
15 ml – bottles (1) – cardboard packs.
20 ml – bottles (1) – cardboard packs.
25 ml – bottles (1) – cardboard packs.
30 ml – bottles (1) – cardboard packs.
40 ml – bottles (1) – cardboard packs.
50 ml – bottles (1) – cardboard packs.
100 ml – bottles (1) – cardboard packs.
3 L – polyethylene canisters.
5 L – polyethylene canisters.
10 L – polyethylene canisters.
Iodopyron [Pharminnovation, LLC (Russia)]
Solution for external use 1%: fl. 50 or 100 ml
Solution for external use 1%: fl. 50 or 100 ml
Marketing Authorization Holder
Pharminnovation, LLC (Russia)
Dosage Form
|
Iodopyron | Solution for external use 1%: fl. 50 or 100 ml |
Dosage Form, Packaging, and Composition
Solution for external use in the form of a film-forming dark brown liquid without odor or with a weak specific odor.
| 1000 ml | |
| Iodine | 14.1 g |
Excipients: potassium iodide – 13.8 g, povidone K17 – 122.1 g, purified water – up to 1000 ml.
50 ml – bottles (1) – cardboard packs.
100 ml – bottles (1) – cardboard packs.
Iodopyron [YUGPHARM, LLC (Russia)]
Solution for external use 1%: fl. 30 ml, 50 ml, 100 ml, 200 ml, 250 ml, 400 ml, 450 ml, 500 ml, or 1000 ml
Solution for external use 1%: fl. 30 ml, 50 ml, 100 ml, 200 ml, 250 ml, 400 ml, 450 ml, 500 ml, or 1000 ml
Marketing Authorization Holder
YUGPHARM, LLC (Russia)
Dosage Form
|
Iodopyron | Solution for external use 1%: fl. 30 ml, 50 ml, 100 ml, 200 ml, 250 ml, 400 ml, 450 ml, 500 ml, or 1000 ml |
Dosage Form, Packaging, and Composition
Solution for external use in the form of a film-forming dark brown liquid, without odor or with a weak specific odor.
| 1000 ml | |
| Iodine | 14.1 g |
Excipients: potassium iodide, povidone K-17, purified water.
30 ml – bottles (1) – cardboard packs.
50 ml – bottles (1) – cardboard packs.
100 ml – bottles (1) – cardboard packs.
200 ml – bottles (1) – cardboard packs.
250 ml – bottles (1) – cardboard packs.
400 ml – bottles (1) – cardboard packs.
450 ml – bottles (1) – cardboard packs.
500 ml – bottles (1) – cardboard packs.
1000 ml – bottles (1) – cardboard packs.
![Iodopyron [Solution] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Iodopyron [Solution] 2")